Effects of butylphthalide sodium chloride injection combined with edaravone dexborneol concentrated solution for injection on neurological function and cerebral blood flow in patients with acute cerebral infarction

Liu Haiyan; Wang Dan; Chen Han

doi:10.3760/j.issn.1673-4777.2026.01.012

Abstract：Objective To investigate the effects of butylphthalide sodium chloride injection combined with edaravone dexborneol concentrated solution for injection on neurological function and cerebral blood flow in patients with acute cerebral infarction(ACI).Methods A total of 89 ACI patients admitted to Nanjing Central Hospital,Jiangsu Province from June 2022 to December 2024 were selected and divided into a control group(44 cases)and an observation group(45 cases)according to the random number table method.On the basis of conventional treatment,the control group was treated with butylphthalide sodium chloride injection,and the observation group was treated with butylphthalide sodium chloride injection plus edaravone dexborneol concentrated solution for injection,with both groups receiving treatment for 2 weeks.The cerebral blood flow status and serum indexes[serum central nervous system-specific protein(S-100β),C-reactive protein(CRP)]levels before and after treatment were compared between the two groups,the prognosis[modified Rankin Scale(mRS)score]within 1 year after treatment was evaluated,and the incidence of adverse reactions after medication was compared between the two groups.Results After treatment,the mean blood flow velocities of the middle cerebral artery,vertebral artery and basilar artery in both groups were higher than those before treatment,and those in the observation group were higher than those in the control group(all P＜0.05).After treatment,the serum levels of S-100β and CRP in both groups were lower than those before treatment(all P＜0.05),and those in the observation group were lower than those in the control group[(0.49±0.14)μg/L vs(0.65±0.17)μg/L,(0.81±0.25)mg/L vs(0.94±0.22)mg/L](all P＜0.05).After treatment,the mRS scores of both groups showed a gradual downward trend,and the mRS scores of the observation group at 3 months,6 months and 1 year after treatment were lower than those of the control group(all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combined treatment of butylphthalide sodium chloride and edaravone dexborneol can effectively promote the recovery of neurological function,accelerate the improvement of cerebral blood flow velocity,significantly reduce the levels of inflammatory indexes in ACI patients.